Delombaerde, D.; Vulsteke, C.; Van de Veire, N.; Vervloet, D.; Moerman, V.; Van Calster, L.; Willems, A.-M.; Croes, L.; Gremonprez, F.; De Meulenaere, A.;
et al. Close Cardiovascular Monitoring during the Early Stages of Treatment for Patients Receiving Immune Checkpoint Inhibitors. Pharmaceuticals 2024, 17, 965.
https://doi.org/10.3390/ph17070965
AMA Style
Delombaerde D, Vulsteke C, Van de Veire N, Vervloet D, Moerman V, Van Calster L, Willems A-M, Croes L, Gremonprez F, De Meulenaere A,
et al. Close Cardiovascular Monitoring during the Early Stages of Treatment for Patients Receiving Immune Checkpoint Inhibitors. Pharmaceuticals. 2024; 17(7):965.
https://doi.org/10.3390/ph17070965
Chicago/Turabian Style
Delombaerde, Danielle, Christof Vulsteke, Nico Van de Veire, Delphine Vervloet, Veronique Moerman, Lynn Van Calster, Anne-Marie Willems, Lieselot Croes, Félix Gremonprez, Astrid De Meulenaere,
and et al. 2024. "Close Cardiovascular Monitoring during the Early Stages of Treatment for Patients Receiving Immune Checkpoint Inhibitors" Pharmaceuticals 17, no. 7: 965.
https://doi.org/10.3390/ph17070965
APA Style
Delombaerde, D., Vulsteke, C., Van de Veire, N., Vervloet, D., Moerman, V., Van Calster, L., Willems, A.-M., Croes, L., Gremonprez, F., De Meulenaere, A., Elzo Kraemer, X., Wouters, K., Peeters, M., Prenen, H., & De Sutter, J.
(2024). Close Cardiovascular Monitoring during the Early Stages of Treatment for Patients Receiving Immune Checkpoint Inhibitors. Pharmaceuticals, 17(7), 965.
https://doi.org/10.3390/ph17070965
